ReCode Therapeutics Achieves First Clinical Proof of mRNA Therapy Activity in Primary Ciliary Dyskinesia
核心洞察
ReCode Therapeutics (搜索) demonstrated the first clinical evidence of biological activity for a genetic medicine in primary ciliary dyskinesia (搜索) (PCD (搜索)), a rare inherited disease with no existing treatments.
The Phase 1b trial showed 57% of patients achieved meaningful improvement in mucociliary clearance (搜索) at 12 weeks, with bronchoscopy confirming restoration of protein and ciliary activity in airways.
This represents the first successful delivery and translation of an inhaled mRNA therapeutic in the human airway, validating ReCode's SORT lipid nanoparticle platform.
ReCode Therapeutics (搜索) has achieved a significant milestone in genetic medicine by demonstrating the first clinical evidence of biological activity for a genetic therapy in primary ciliary dyskinesia (搜索) (PCD (搜索)) patients. The clinical-stage company presented groundbreaking data from its RCT1100 inhaled mRNA program at the American Thoracic Society 2026 International Conference, marking the first successful delivery and translation of an mRNA therapeutic in the human airway.
Clinical Trial Results Show Meaningful Improvement
Data from ReCode's RCT1100-103 Phase 1b trial, conducted across sites in Denmark, Germany, and the United States, demonstrated that 57% of patients achieved meaningful improvement in mucociliary clearance (搜索) at 12 weeks. Bronchoscopy procedures confirmed restoration of protein and ciliary activity in the airways of treated patients. Importantly, restoration of protein was correlated with positive changes in mucociliary clearance, indicating a direct therapeutic mechanism.
The therapy demonstrated a favorable safety profile, with no serious adverse events reported during the study period. The drug was described as safe and well-tolerated across all participants.
"For the first time, we demonstrated the promise of inhaled genetic medicine delivery to the lung, and downstream biologic activity in PCD (搜索) patients," said Shehnaaz Suliman, chief executive officer of ReCode. "This is substantial validation of ReCode's SORT LNP platform and opens the door to a new treatment paradigm for PCD patients."
Supporting Clinical Evidence
The RCT1100-103 trial was supported by comprehensive data from two earlier studies. A single-dose Phase 1a study (RCT1100-101) in healthy volunteers and PCD (搜索) patients, along with a multiple-dose Phase 1b study (RCT1100-102) in PCD patients, established the safety and tolerability of RCT1100 across dose levels up to 5 mg administered three times weekly. These studies showed no serious or treatment-emergent adverse events of Grade 3 or higher.
Additionally, a separate longitudinal observational study of 25 adults with confirmed PCD (搜索) found that mucociliary clearance (搜索) values were consistently low regardless of underlying genotype, consistent with baseline values in the RCT1100-103 study. This data supports mucociliary clearance as a reliable measure for evaluating disease-modifying therapies in future PCD studies.
Addressing Significant Unmet Medical Need
Primary ciliary dyskinesia (搜索) represents a substantial unmet medical need, affecting an estimated 1 in 7,500 people across diverse ethnicities, with approximately 45,000 patients in the United States. The rare genetic disease is characterized by deficient mucociliary clearance (搜索), chronic respiratory tract infections, bronchiectasis, and declining respiratory function. Mutations in more than 50 genes result in dysfunctional cilia (搜索) and loss of mucociliary clearance.
PCD (搜索) is a progressive disorder that worsens over time, and currently no cure or disease-modifying treatments exist. Due to the lack of widespread screening, approximately 80% of people with PCD are thought to be undiagnosed, highlighting the critical need for both improved diagnostic approaches and therapeutic interventions.
Platform Technology Validation
The clinical success validates ReCode's proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform, which enables highly precise and targeted delivery of genetic medicines directly to organs, tissues, and cells implicated in disease. This precision delivery approach is designed to improve efficacy and potency of genetic therapies.
"These data represent a foundational advancement for PCD (搜索) patients," said John Matthews, chief medical officer of ReCode. "This has been a huge collaborative effort with the PCD community, and we are grateful to the patients and investigators who participated in this study."
The company's achievement was also recognized through an oral showcase presentation at the ATS 2026 Respiratory Innovation Summit, further highlighting the significance of this therapeutic breakthrough in the respiratory medicine field.